Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here
HDT Bio Suit Not An Impediment
With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip
You may also be interested in...
Zydus is developing a novel ADC, one of the most challenging but rewarding treatment modalities today as others in the class like Kadcyla and Enhertu prove. The Indian firm's managing director spoke to Scrip about R&D efforts, recent policy moves and gains from making the world’s first approved recombinant plasmid DNA vaccine.
While Moderna plans preclinical studies and Tonix Pharma’s candidate is to enter trials in H1, Bavarian Nordic is seeking US and Indian manufacturing partners for its approved monkeypox vaccine. Scrip examines if the disease presents an opportunity for vaccine makers, like COVID-19 did or it could go the H1N1 way
A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.